Determining the Comparative Efficacy of Adenosine Analogues in Reducing Coronavirus Replication by Interfering Viral RNA Dependent RNA Polymerase Activity

Vaccines against infectious viral diseases are good in preventing those illnesses, however their application is not recommended in curing the ongoing infection. Antiviral drugs such as nucleotide analogs have been successfully used in treating various viral infections. Taking this background, current study is designed to evaluate the antiviral efficacy of adenosine analogues such as Remdesivir, Galidesivir, and 2-Chloroadenosine in inhibiting the human (HOC43) and animal coronavirus (Porcine Epidemic Diarrhea Virus: Colorado strain) replication by interfering viral RNA dependent RNA polymerase (RdRp) activity. Molecular docking was performed to determine the interaction of adenosine analogues with viral RdRp. While In vitro efficacy for these adenosine analogues in reducing RdRp activity will be performed using affinity purified, mammalian expressed recombinant RdRp protein. The antiviral efficacy for these adenosine analogues will also be measured by determining their effect on virus titer and virus plaque assay along with their effect on cellular toxicity.https://ecommons.udayton.edu/stander_posters/3131/thumbnail.jp